Market accessCompany release

Citius Oncology reports LYMPHIR wholesaler purchases up 120% in latest quarter

🇺🇸 Citius Oncology, Inc. (CTOR) · Mon 26 Oct 2026

Preliminary, unaudited figures show wholesalers bought 792 LYMPHIR units in the quarter to 30 September 2026, with 54 institutions having ordered the lymphoma therapy.

Citius Oncology, Inc. said on 26 October 2026 that wholesalers purchased 792 units of LYMPHIR (denileukin diftitox-cxdl) in the quarter ended 30 September 2026. That compares with 360 units in the preceding quarter, an increase of 120%.

The company described the figures as preliminary and unaudited. They measure units bought by wholesalers rather than any reported measure of patient use.

The number of institutions that have ordered the product rose to 54 from 44 in the previous quarter. Citius Oncology said it is aiming to secure formulary placement at 100 priority institutions by the end of the calendar year.

LYMPHIR is FDA-approved and was launched in December 2025. It is indicated for adults with relapsed or refractory Stage I-III cutaneous T-cell lymphoma who have received at least one prior systemic therapy.

What it means for your team

  • Early uptake data are preliminary and unaudited, so they should be treated as indicative until the company reports final figures.
  • Wholesaler purchases are a supply-chain indicator, not a measure of patient exposure, so they say little about real-world safety data volumes.
  • Formulary placement is the company's stated near-term goal, with 100 priority institutions targeted by calendar year-end; market-access teams may want to track progress against it.

Company's press release (SEC filing): Citius Oncology, Inc. ↗

Article written by VigiEye from the official source (Citius Oncology, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Market access All →